Cargando…
Induction of high titred, non-neutralising antibodies by self-adjuvanting peptide epitopes derived from the respiratory syncytial virus fusion protein
Respiratory syncytial virus (RSV) causes severe lower respiratory tract illness in infants and young children. The significant morbidity and mortality rates associated with RSV infection make an effective RSV vaccine development a priority. Two neutralising antibody binding sites, Ø and II, located...
Autores principales: | Jaberolansar, Noushin, Chappell, Keith J., Watterson, Daniel, Bermingham, Imogen M., Toth, Istvan, Young, Paul R., Skwarczynski, Mariusz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593926/ https://www.ncbi.nlm.nih.gov/pubmed/28894111 http://dx.doi.org/10.1038/s41598-017-10415-w |
Ejemplares similares
-
Combinatorial F-G Immunogens as Nipah and Respiratory Syncytial Virus Vaccine Candidates
por: Isaacs, Ariel, et al.
Publicado: (2021) -
Carbohydrate Immune Adjuvants in Subunit Vaccines
por: Bashiri, Sahra, et al.
Publicado: (2020) -
Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants
por: Pallett, Scott J C, et al.
Publicado: (2022) -
Peptide-Based Vaccine against SARS-CoV-2: Peptide Antigen Discovery and Screening of Adjuvant Systems
por: Shalash, Ahmed O., et al.
Publicado: (2022) -
Antibodies to neutralising epitopes synergistically block the interaction of the receptor‐binding domain of SARS‐CoV‐2 to ACE 2
por: Pandey, Manisha, et al.
Publicado: (2021)